Disease · MONDO_0017844
Comparisons in its trials11
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 11 of 11
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Bexarotene Exposed vs Bexarotene Naive: deaths from any cause | 3 of 79 | 3 of 60 | 139 | NCT00425555 | Trial comparisons |
| Bexarotene Exposed vs Bexarotene Naive: serious adverse events | 33 of 79 | 23 of 60 | 139 | NCT00425555 | Trial comparisons |
| Parts 2 and 3 : Cutaneous T-cell Lymphoma (CTCL) vs Parts 2 and 3: T-cell Lymphoma (TCL): Parts 2 and 3: Overall Response Rate (ORR)-Olsen 2011-Disease Indication | 2 of 21 | 5 of 29 | 50 | NCT02663518 | Trial comparisons |
| Group I (Pembrolizumab, Interferon Gamma-1b) vs Group II (Pembrolizumab, Interferon Gamma-1b): Overall Response Rate (ORR) | 6 of 16 | 0 of 12 | 28 | NCT03063632 | Trial comparisons |
| Group I (Pembrolizumab, Interferon Gamma-1b) vs Group II (Pembrolizumab, Interferon Gamma-1b): Incidence of Adverse Events | 15 of 16 | 12 of 12 | 28 | NCT03063632 | Trial comparisons |
| Group I (Pembrolizumab, Interferon Gamma-1b) vs Group II (Pembrolizumab, Interferon Gamma-1b): deaths from any cause | 4 of 16 | 6 of 12 | 28 | NCT03063632 | Trial comparisons |
| Group I (Pembrolizumab, Interferon Gamma-1b) vs Group II (Pembrolizumab, Interferon Gamma-1b): serious adverse events | 4 of 16 | 5 of 12 | 28 | NCT03063632 | Trial comparisons |
| Part 2: Myelodysplastic Syndrome (MDS) vs Part 2: Myeloproliferative Neoplasms (MPN): Part 2: Overall Response Rate (ORR)-Savona 2015- Disease Indication | 0 of 6 | 1 of 3 | 9 | NCT02663518 | Trial comparisons |
Dose Level 1 (Interleukin-15 2mcg/kg/Day) vs Dose Level 2 (Interleukin-15 4mcg/kg/Day): Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0) | 3 of 3 | 3 of 3 | 6 | NCT04185220 | Trial comparisons |
| Dose Level 1 (Interleukin-15 2mcg/kg/Day) vs Dose Level 2 (Interleukin-15 4mcg/kg/Day): deaths from any cause | 2 of 3 | 1 of 3 | 6 | NCT04185220 | Trial comparisons |
| Dose Level 1 (Interleukin-15 2mcg/kg/Day) vs Dose Level 2 (Interleukin-15 4mcg/kg/Day): serious adverse events | 3 of 3 | 2 of 3 | 6 | NCT04185220 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0017844/comparisons